https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=19319
Author Archives: lwm100
Phase 2/3 study with opaganib approved in Russia for COVID-19; United States trial rapidly enrolling
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16275
Phase 2/3 Study with opaganib approved in UK for COVID-19
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16270
Phase 2/3 Clinical Trial with Opaganib for COVID-19 Submitted
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=16265
Opaganib (ABC294640) Successfully Treats Patients with COVID-19 in Israel, Clinical Trial Approved in the U.S.
https://www.globenewswire.com/news-release/2020/05/08/2030275/0/en/RedHill-Biopharma-Receives-FDA-Approval-for-COVID-19-Clinical-Study-with-Opaganib-in-the-U-S.html
Update on ABC294640 (opaganib)
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=13253
Presentation on ABC294640 (opaganib) for Multiple Myeloma
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1384&PID=0&IID=10194
Initiation of Phase IIa Study with ABC294640 (opaganib) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1365&PID=0&IID=6163
Peer-reviewed publication of the positive ABC294640 (opaganib) Phase 1 study results in advanced solid tumors.
https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=1365&PID=0&IID=5112
Apogee Licenses ABC294640 to RedHill Biopharma
Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma. Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications. http://globenewswire.com/news-release/2015/03/31/720531/10126995/en/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html